Oral Cryotherapy for Management of Chemotherapy-induced Oral Mucositis in Haematopoietic Cell transplantation: a Systematic Review

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Apr 23

PMID 35459129

Authors

Faizah Jabr Alsulami

Sadr Ul Shaheed

Affiliations

Soon will be listed here.

Abstract

Background: Oral mucositis (OM) is known to be the most common and challenging side effect of conditioning chemotherapy in haematopoietic cell transplant (HCT). This side effect causes significant morbidity and may delay the treatment plan, as well as increase therapeutic expenses. There are few clinical trials in the literature that indicate any kind of treatment or prevention methods are effective. Therefore, the aim of this study is to perform a systematic review of literature and examine the effectiveness of oral cryotherapy (OC) in management of chemotherapy-induced OM in patients with haematological malignancies undergoing a HCT.

Methods: A systematic literature search was conducted, using the electronic databases PubMed, Embase, MEDLINE and Scopus. A total of 322 papers were identified and 9 papers were analysed based on defined inclusion and exclusion criteria. The quality of the chosen primary studies was appraised using the COCHRANE risk of bias assessment tool.

Results: Nine randomized controlled trials, analysing 658 participants; control group (n = 289, age mean ± SD; 41.15 ± 21) and treatment group (n = 369, age mean ± SD; 39.15 ± 20), were included in this systematic review. Seven studies had significantly addressed the effectiveness of OC (p value < 0.05), in reducing the incidence of developing severe OM in the adult population undergoing HCT, especially when the conditioning regimen protocols included high dose of alkylating agent such as melphalan.

Conclusion: This review supports the use of OC for prevention of OM in patients undergoing HCT, with high-dose of melphalan conditioning protocols. It is recommended that more studies be conducted to compare efficacy and duration of OC with other chemotherapeutic agents with relatively short plasma half-lives. The heterogeneity of the trials demonstrated the need to regulate the validated assessment tools and similar interventions that would enable comparisons and analyses of treatment effects based on well-designed RCTs.

Citing Articles

[Clinical analysis of oral mucositis after secondary allogeneic hematopoietic stem cell transplantation in patients with hematological diseases].

Zhu X, Wang J, Fu H, Han T, Xu Z, Zhang X Zhonghua Xue Ye Xue Za Zhi. 2025; 45(12):1078-1084.

PMID: 39765347 PMC: 11886692. DOI: 10.3760/cma.j.cn121090-20240701-00240.

Effectiveness of cryotherapy in preventing oral mucositis in pediatric cancer patients in Jordan: a randomized controlled trial.

Banat K, Al-Haja H, Ananbeh M, Abdullah E, Alloubani A Child Health Nurs Res. 2024; 30(4):245-254.

PMID: 39477231 PMC: 11532350. DOI: 10.4094/chnr.2024.004.

Photobiomodulation therapy to prevent oral mucositis and functional impairment in adult patients with haematological cancer undergoing haematopoietic stem cell transplantation: randomised trial protocol.

Lopez-Espinoza T, Sacomori C, Araya-Castro P, Quintiliano-Scarpelli D, Roldan P, Pena-Espinoza M BMJ Open. 2024; 14(10):e088073.

PMID: 39461860 PMC: 11529764. DOI: 10.1136/bmjopen-2024-088073.

Efficacy of Low-Level Laser Therapy for Oral Mucositis in Hematologic Patients Undergoing Transplantation: A Single-Arm Prospective Study.

Nishi H, Horikoshi S, Ohta K, Yoshida T, Fukushima N, Oshita K J Pers Med. 2023; 13(11).

PMID: 38003918 PMC: 10672422. DOI: 10.3390/jpm13111603.

Mucositis and Infection in Hematology Patients.

Blijlevens N, de Mooij C Int J Mol Sci. 2023; 24(11).

PMID: 37298545 PMC: 10253974. DOI: 10.3390/ijms24119592.

References

Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A . Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2005; 13(4):266-9. DOI: 10.1007/s00520-004-0726-y. View

Lalla R, Sonis S, Peterson D . Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2007; 52(1):61-77, viii. PMC: 2266835. DOI: 10.1016/j.cden.2007.10.002. View

Correa M, Cheng K, Chiang K, Kandwal A, Loprinzi C, Mori T . Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019; 28(5):2449-2456. DOI: 10.1007/s00520-019-05217-x. View

Wang L, Gu Z, Zhai R, Zhao S, Luo L, Li D . Efficacy of oral cryotherapy on oral mucositis prevention in patients with hematological malignancies undergoing hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. PLoS One. 2015; 10(5):e0128763. PMC: 4449217. DOI: 10.1371/journal.pone.0128763. View

Biagioli V, Piredda M, Mauroni M, Alvaro R, De Marinis M . The lived experience of patients in protective isolation during their hospital stay for allogeneic haematopoietic stem cell transplantation. Eur J Oncol Nurs. 2016; 24:79-86. DOI: 10.1016/j.ejon.2016.09.001. View

Atilla E, Ataca Atilla P, Demirer T . A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations. Balkan Med J. 2017; 34(1):1-9. PMC: 5322516. DOI: 10.4274/balkanmedj.2017.0055. View

Lu Y, Zhu X, Ma Q, Wang J, Jiang P, Teng S . Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study. Support Care Cancer. 2019; 28(4):1747-1754. DOI: 10.1007/s00520-019-04966-z. View

Peterson D, Ohrn K, Bowen J, Fliedner M, Lees J, Loprinzi C . Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer. 2012; 21(1):327-32. DOI: 10.1007/s00520-012-1562-0. View

Riley P, McCabe M, Glenny A . Oral Cryotherapy for Preventing Oral Mucositis in Patients Receiving Cancer Treatment. JAMA Oncol. 2016; 2(10):1365-1366. DOI: 10.1001/jamaoncol.2016.2680. View

10.

Marchesi F, Tendas A, Giannarelli D, Viggiani C, Gumenyuk S, Renzi D . Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Bone Marrow Transplant. 2016; 52(1):154-156. DOI: 10.1038/bmt.2016.207. View

11.

Passweg J, Baldomero H, Chabannon C, Basak G, de la Camara R, Corbacioglu S . Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021; 56(7):1651-1664. PMC: 8263343. DOI: 10.1038/s41409-021-01227-8. View

12.

Cutler C, Li S, Kim H, Laglenne P, Szeto K, Hoffmeister L . Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005; 11(5):383-8. DOI: 10.1016/j.bbmt.2005.02.006. View

13.

Johansson J, Bratel J, Hardling M, Heikki L, Mellqvist U, Hasseus B . Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial. Bone Marrow Transplant. 2019; 54(9):1482-1488. DOI: 10.1038/s41409-019-0468-6. View

14.

Morawska K, Goirand F, Marceau L, Devaux M, Cueff A, Bertaut A . 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. Oncotarget. 2018; 9(14):11559-11571. PMC: 5837758. DOI: 10.18632/oncotarget.24338. View

15.

Alvarino-Martin C, Sarrion-Perez M . Prevention and treatment of oral mucositis in patients receiving chemotherapy. J Clin Exp Dent. 2014; 6(1):e74-80. PMC: 3935910. DOI: 10.4317/jced.51313. View

16.

Sharifi H, Heydari A, Salek R, Emami Zeydi A . Oral cryotherapy for preventing chemotherapy-induced oral mucositis: An effective but yet neglected strategy. J Cancer Res Ther. 2017; 13(2):386-387. DOI: 10.4103/0973-1482.188301. View

17.

Gyurkocza B, Sandmaier B . Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014; 124(3):344-53. PMC: 4102707. DOI: 10.1182/blood-2014-02-514778. View

18.

Schmidt V, Niederwieser D, Schenk T, Behre G, Klink A, Pfrepper C . Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018; 53(9):1188-1192. DOI: 10.1038/s41409-018-0135-3. View

19.

Salvador P, Azusano C, Wang L, Howell D . A pilot randomized controlled trial of an oral care intervention to reduce mucositis severity in stem cell transplant patients. J Pain Symptom Manage. 2012; 44(1):64-73. DOI: 10.1016/j.jpainsymman.2011.08.012. View

20.

Fadda G, Campus G, Luglie P . Risk factors for oral mucositis in paediatric oncology patients receiving alkylant chemotherapy. BMC Oral Health. 2006; 6:13. PMC: 1629008. DOI: 10.1186/1472-6831-6-13. View